CANY
CCCC icon

Caxton Associates (New York)’s C4 Therapeutics CCCC Stock Holding History

Caxton Associates (New York)’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$75.6K Hold
21,002
– – ﹤0.01% 472
2024
Q3 		$120K Hold
21,002
– – ﹤0.01% 506
2024
Q2 		$97K Hold
21,002
– – ﹤0.01% 462
2024
Q1 		$172K Buy
+21,002
New +$163K 0.01% 428
2023
Q3 		– Sell
-26,721
Closed -$73.5K – 424
2023
Q2 		$73.5K Sell
26,721
-12,204
-31% -$39.2K 0.01% 466
2023
Q1 		$122K Buy
+38,925
New +$229K 0.02% 453

Other funds holding CCCC

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Caxton Associates (New York)'s CCCC Position: Q4 2024 in Review

Caxton Associates (New York) held its C4 Therapeutics (CCCC) position steady in Q4 2024 at 21,002 shares worth $75.6K. The position accounts for ﹤0.01% of the portfolio, ranked #472.

Caxton Associates (New York) first reported a position in CCCC in Q1 2023 and has held it in 6 quarters since. The position peaked at $172K in Q1 2024. 113 funds tracked by Wall St. Rank hold CCCC as of Q4 2024.

  • Caxton Associates (New York) held 21,002 shares of C4 Therapeutics worth $75.6K as of Q4 2024.
  • Caxton Associates (New York) left its C4 Therapeutics share count unchanged in Q4 2024.
  • C4 Therapeutics made up ﹤0.01% of Caxton Associates (New York)'s portfolio in Q4 2024, its #472 holding.
  • Caxton Associates (New York) first reported a position in C4 Therapeutics in Q1 2023 and has held it in 6 quarters since.
  • Caxton Associates (New York)'s C4 Therapeutics position peaked at $172K in Q1 2024.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.